NASDAQ · Biotechnology

CRIS (CRIS) Stock

$4.69 -4.09% NASDAQ: CRIS Healthcare

Valuation

MetricValue
Price$4.69
Market Cap$9.14M
P/E Ratio-0.35
P/B Ratio0.63
P/S Ratio0.78
EPS (TTM)$0.00
52-Week High$6.93
52-Week Low$0.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-693.93%
ROA-62.06%
ROCE-660.00%
Gross Margin99.45%
Operating Margin-4.85%
Net Margin-3.00%
Debt/Equity0.11
Current Ratio0.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$11.0M$10.0M$10.0M$11.0M$9.0M
Operating Profit$-42.0M$-53.0M$-48.0M$-45.0M$-33.0M
Net Profit$-45.0M$-57.0M$-47.0M$-43.0M$-8.0M
EPS$-9.92$-12.14$-8.96$-6.88$-0.58
Op Margin-395.0%-521.8%-482.2%-408.3%-348.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$162.0M$109.0M$77.0M$41.0M$20.0M
Total Liabilities$72.0M$62.0M$58.0M$47.0M$15.0M
Cash$40.0M$20.0M$27.0M$20.0M$5.0M
Borrowings$5.0M$4.0M$3.0M$3.0M$2.0M

Latest News

Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia MT Newswires · Jul 6, 2026 Curis Consents First Six Patients in TakeAim CLL Study PR Newswire · Jul 6, 2026 Curis opens 11 sites for emavusertib combo in TakeAim CLL trial Clinical Trials Arena · Jun 29, 2026 BC-Most Active Stocks Associated Press · Jun 26, 2026 Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split PR Newswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-38.0M$-54.0M$-38.0M$-40.0M$-27.0M
Investing Cash Flow$-48.0M$33.0M$38.0M$29.0M$3.0M
Financing Cash Flow$-4.0M$0$-7.0M$0$0
Net Cash Flow$-90.0M$-20.0M$7.0M$-7.0M$-15.0M
Free Cash Flow$-38.0M$-55.0M$-38.0M$-40.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.42
EV / EBITDA0.16
FCF Yield-528.66%
Quick Ratio1.00
Interest Coverage-16.50
Return 1Y-87.15%
Return 3Y-98.52%
Return 5Y-99.84%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASBP $7.26 +3.13% -0.74 $837601 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
BCTX $3.53 +1.73% -0.04 $6.65M 0.00%
CTXR $0.57 -9.81% -0.68 $6.37M 0.00%
ENTOEntero Therapeutics, Inc. $2.85 -5.00% -0.82 $13.58M 0.00%

About CRIS

CRIS is led by CEO James E. Dentzer, employs 34 people, headquartered in US, publicly traded since 2000.

CRIS stock trades at $4.69 with a market capitalization of $9.14M. The stock is valued at a price-to-earnings (P/E) ratio of -0.35, price-to-book of 0.63, price-to-sales of 0.78. Over the past 52 weeks the stock has ranged between $0.19 and $6.93, and currently trades 32.3% below its 52-week high.

On profitability, CRIS generates a return on equity (ROE) of -693.93%, return on capital employed of -660.00%, an operating margin of -4.85%, a net profit margin of -3.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides